“Key aspects include tracking blood sugar levels, particularly in diabetic patients, as elevated glucose can complicate ...

Emerging applications and growing demand for breath biopsy devices are due to a shift toward precision medicine, as well as expanding applications beyond oncology. Innovations in the biopsy devices ...

Cardinal Health plans to buy two companies that will expand its diabetes and gastroenterology businesses as part of an ...

The health-tech industry’s long-term growth is fueled by the growing need for cutting-edge technologies to address critical ...

"His vision is compelling, to unite surgical oncology under Lumicell’s imaging platform and ... management consulting and ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Thank you for standing by and welcome to Heron Therapeutics ...

Beyond Air ( (XAIR) ) has released its Q2 earnings. Here is a breakdown of the information Beyond Air presented to its investors. Beyond Air, ...

The office of President is elected by the membership; new leadership terms began at the Annual Membership Meeting on Friday, ...

Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024.

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...